Comparison of bacteremic pneumonia caused by Escherichia coli and Klebsiella pneumoniae: A retrospective study
- PMID: 38438206
- PMCID: PMC11115389
- DOI: 10.15537/smj.2024.45.3.20230428
Comparison of bacteremic pneumonia caused by Escherichia coli and Klebsiella pneumoniae: A retrospective study
Abstract
Objectives: To compare the prognosis of bacteremic pneumonia caused by Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) pathogens.
Methods: A retrospective analysis was carried out on the clinical data of 162 patients who were diagnosed with bacterial pneumonia caused by either K. pneumoniae or E. coli between 2016-2019. The primary outcome of the analysis was the patients' 30-day mortality rate.
Results: There were 82 patients in the E. coli bacteremic pneumonia (E. coli-BP) group and 80 patients in the K. pneumoniae bacteremic pneumonia (KP-BP) group. The 30-day mortality rate was 43.75% (n=35/80) in the KP-BP group and 21.95% (n=18/82) in the E. coli-BP group (p<0.001). Following the adjustment for confounding variables in 4 distinct models, the hazard ratios for the primary outcome in KP-BP were determined to be 0.70 (95% confidence interval [CI]: [0.44-1.02]) in Model 1, 0.72 (95% CI: [0.46-1.14]) in Model 2, 0.99 (95% CI: [0.57-1.73]) in Model 3, and 1.22 (95% CI: [0.69-2.18]) in Model 4.
Conclusion: Patients diagnosed with KP-BP exhibited a similar prognosis as those diagnosed with E. coli-BP. For patients with KP-BP, the risk of mortality was significantly higher for those who were in the intensive care unit, were infected with carbapenem-resistant strains, or had a high sequential organ failure assessment score. In patients with E. coli-BP, the Pitt bacteremia score was strongly associated with the 30-day mortality rate.
Keywords: 30-day mortality; Escherichia coli; Klebsiella pneumoniae; bacteremic pneumonia; risk factors.
Copyright: © Saudi Medical Journal.
Figures
References
-
- Forstner C, Patchev V, Rohde G, Rupp J, Witzenrath M, Welte T, et al. . Rate and predictors of bacteremia in Afebrile community-acquired pneumonia. Chest 2020; 157: 529-539. - PubMed
-
- Amati F, Restrepo MI.. Emerging resistance of gram negative pathogens in community-acquired pneumonia. Semin Respir Crit Care Med 2020; 41: 480-495. - PubMed
-
- Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. . Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45-e67. - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
